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Abstract
Germline mutations in tumor suppressor genes, or less
frequently oncogenes, have been identified in up to 19
familial cancer syndromes including Li -Fraumeni syn-
drome, familial paraganglioma, familial adenomatous
polyposis coli and breast and ovarian cancers. Multiple
genes have been associated with some syndromes as
approximately 26 genes have been linked to the devel-
opment of these familial cancers. With this increased
knowledge of the molecular determinants of familial
cancer comes an equal expectation for efficient genetic
screening programs. We have trialled denaturing high-
performance liquid chromatography (dHPLC) as a tool
for rapid germline mutation scanning of genes impli-
cated in three familial cancer syndromes — Cowden
syndrome (PTEN mutation), multiple endocrine neo-
plasia type 2 (RET mutation) and von Hippel -Lindau
disease (VHL mutation). Thirty- two mutations, includ-
ing 21 in PTEN, 9 in RET plus a polymorphism, and 2 in
VHL, were analyzed using the WAVE DNA fragment
analysis system with 100% detection efficiency. In the
case of the tumor suppressor gene PTEN, mutations
were scattered along most of the gene. However,
mutations in the RET proto-oncogene associated with
multiple endocrine neoplasia type 2 were limited to
specific clusters or ‘‘hot spots.’’ The use of GC-clamped
primers to scan for mutations scattered along PTEN
exons was shown to greatly enhance the sensitivity of
detection of mutant hetero- and homoduplex peaks at a
single denaturation temperature compared to fragments
generated using non–GC-clamped primers. Thus, when
scanning tumor suppressor genes for germline muta-
tion using dHPLC, the incorporation of appropriate GC-
clamped primers will likely increase the efficiency of
mutation detection. Neoplasia (2001) 3, 236–244.
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Introduction
The identification of genes associated with familial cancer
syndromes has created a commensurate requirement for the
efficient scanning of these genes in at- risk family members.
Familial cancers account for up to 10% of all malignancies.
Germline mutation in a tumor suppressor or, less frequently
an oncogene, has been identified as the primary genetic
event linked to an increased risk of developing specific
malignancies in approximately 19 familial syndromes. In
some cases, such as hereditary nonpolyposis colon cancer
(HNPCC), mutation of more than one gene has been
associated with the clinical phenotype, implicating approx-
imately 26 genes as ‘‘caretakers’’ or ‘‘gatekeepers’’ for the
development of human cancer in the familial setting (Ref. [1 ],
reviewed in Ref. [2] ). It has been estimated that as many as
50 different genes may eventually be identified where carriers
of heterozygous mutations will have an increased risk of
developing cancer [3 ].
With this increased clarification of the molecular basis of
many inherited cancers comes the opportunity to offer
efficient genetic screening programs coupled with the
collection of family histories that will allow for noninvasive
assessment of asymptomatic at - risk individuals, increase the
diagnostic power of clinicians and permit directed cancer
surveillance. We, and others, have previously reported
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genetic screening of patients and their relatives with three
distinct inherited cancer syndromes — multiple endocrine
neoplasia type 2 (MEN 2) [OMIM#171400] and germline
mutation of the proto-oncogene RET; von Hippel -Lindau
disease (VHL) [OMIM#193300] and germline mutation of
the tumor suppressor VHL; and Cowden syndrome (CS)
[OMIM#158350] with germline mutation of the tumor
suppressor PTEN [4–7]. In addition, Bannayan-Riley-
Ruvalcaba syndrome (BRR) [OMIM#153480], has been
shown to be part of the clinical spectrum of CS, and
approximately half carry a germline mutation of PTEN [8 ].
The most common clinical features of MEN 2, VHL, CS, and
BRR are summarized in Table 1.
In the case of the tumor suppressor genes PTEN and
VHL, mutations are scattered along the majority of the gene.
However, in contrast, mutations in the RET proto-oncogene
associated with MEN 2 are targeted to specific codons. The
mutation type, location and the frequency with which these
genes are mutated in the germline in association with a
familial cancer syndrome are summarized in Table 2.
Comprehensive mutation summaries for these and addi-
tional genes can be located at the Human Gene Mutation
Database (HGMD) website, http: / /www.uwcm.ac.uk /
uwcm/mg/hgmd0.html.
In this study, we report the efficient use of denaturing
high-performance liquid chromatography (dHPLC) for
mutation scanning in three familial cancer syndromes, and
their variants, where mutations are either clustered in ‘‘hot
spots’’ or scattered along the entire gene.
Materials and Methods
Patients and Samples
Blood samples from the probands of 21 families with CS
and/or BRR, 9 families with MEN 2, and 2 families with VHL
were collected for analysis. Constitutional DNAwas extracted
from blood leucocytes using standard techniques [18].
Germline mutation of PTEN had previously been reported
in 20 of the CS or BRR families identified using denaturing
gradient gel electrophoresis (DGGE), temporal temperature
gel electrophoresis (TTGE), or sequencing [4,5 ] (Table 3).
AllRETmutants had previously been reported by us or others
[6,13]. The two VHL mutants described in this study had
previously been reported by others [14,19] (http: / /
www.uwcm.ac.uk/uwcm/mg/hgmd0.html) (Table 3). In
addition, blood was collected from four at - risk members of
one of the VHL families for analysis.
Polymerase Chain Reaction and Sequencing
Primer sequences and PCR conditions for the amplifica-
tion of GC-clamped PTEN fragments have been previously
reported [20–23]. In addition, four PTEN exons, or
amplicons, and flanking intronic sequences were amplified
Table 1. Common Clinical Features of CS, the Related Syndrome BRR, MEN 2, and VHL.
Syndrome Tumor Types Other Features
Cowden Syndrome (CS) o breast cancer o trichilemmomas
o thyroid cancer o papillomatous papules
o endometrial cancer o Lhermitte -Duclos disease
o gastrointestinal polyps
o lipomatosis
o macrocephaly
Bannayan -Riley -Ruvalcaba Syndrome (BRR) o macrocephaly
o lipomatosis
o pigmented macules of the glans penis
o hemangioma
o gastrointestinal polyps
o mild mental retardation
Multiple endocrine neoplasia type 2 (MEN 2)
FMTC* o medullary thyroid carcinoma
MEN 2A o medullary thyroid carcinoma o parathyroid hyperplasia
o pheochromocytoma
MEN 2B o medullary thyroid carcinoma o Marfanoid habitus
o pheochromocytoma o mucosal neuromas
von Hippel - Lindau disease (VHL ) o pheochromocytoma o angiomata of the retina
o cerebellar hemangioblastoma
o renal cell carcinoma
o spinal hemangioblastoma
o endolymphatic sac tumors ( rare )
*FMTC — familial medullary thyroid carcinoma.
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using non–GC-clamped primers, identical to the GC-
clamped primers previously published, however, missing
the GC-clamp as follows: amplicon 5I, 5IFnogc 50 -TTT TTT
CTT ATT CTG AGG TTA TC-30 and reverse primer as
previously reported [21]; amplicon 5II, 5IIRnogc 50 -GAA
GAG GAA AGG AAA AAC ATC-30 and forward primer as
previously reported [21]; exon 7, 7Fnogc 50 -AAT AAT ACT
GGT ATG TAT TTA AC-30 and 7Rnogc 50 -GAT ATT TCT
CCC AAT GAA AG-30; exon 8, 8Fnogc 50 -GTT TCA CTT
TTG GGT AAA TA-30 and 8Rnogc 50 -TGC TTC GAA ATA
ATA CAT AA-30. PCR conditions were identical to those
previously published for the amplification of GC-clamped
PTEN fragments [20,21,23].
PCR conditions and primer sequences for amplification of
the RET proto-oncogene have, in general, been previously
reported. Exon 10 was amplified using 7F and 7R with the
addition of 10% dimethyl sulfoxide (Sigma Chemical Co,
Castle Hill, NSW, Australia ) [24]; exon 11 was amplified
using 8AR [24] and 11F, 50 -AGC CAT GAG GCA GAG CAT
AC-30; exon 15 was amplified using 17B and 17G [25], and
exon 16 was amplified using fRET16 and rRET16 [26].
Primer sequences for the amplification of VHL exon 3
were modified from those previously published [27],
specifically 40Fmod, 50 -CTG AGA CCC TAG TCT GCC
ACT GAG-30 and 41Rmod, 50 -CAA AAG CTG AGA TGA
AAC AGTGTA-30. PCR reaction conditions consisted of one
cycle of denaturation at 948C for 5 minutes, followed by 40
cycles of denaturation at 948C for 1 minute, annealing at
618C for 1 minute and extension at 728C for 1 minute,
followed by 728C for 10 minutes. The final concentration of
PCR reagents were as follows: 0.4 M of each primer, 0.05
mM of each deoxyribonucleotide triphosphate, 1PCR
buffer without MgCl2 (Perkin-Elmer Corp., Norwalk, CT),
1.5 mM MgCl2 and 0.5 l of Taq polymerase (5 U/l )
(Perkin-Elmer). PCR reactions were performed in a final
volume of 50 l.
All PCR products were generated using a MJ Peltier
Thermal Cycler PTC-100 (MJ Research, Watertown, MA).
PCR products destined for dHPLC analysis underwent
additional cycling after amplification, consisting of a denatu-
ration step of 948C for 5 minutes followed by ramping to 258C
over 45 minutes to allow the formation of homo- and
heteroduplexes in samples heterozygous for a mutant allele.
No additional purification procedures were required. Product
sizes ranged from 178 to 396 nucleotides. PCR products
destined for sequence analysis were purified using the
Wizard PCR Preps DNA Purification System (Promega,
Madison, WI). Direct sequencing of these products was
performed using the ABI Prism BigDye Terminator cycle
sequencing ready reaction kit (Applied Biosystems, Perkin-
Elmer). Purified cycle sequencing products were electro-
phoresed on 4.8% PAGE Plus gels (Amresco, Cleveland,
OH) and analyzed on a 377XL automated DNA sequencer
(Applied Biosystems, Perkin-Elmer).
Table 2. Causative Genes, Their Mutation Type, Location and Mutation Frequency, in CS, BRR, MEN 2, and VHL.
Syndrome Gene Exons Mutation Frequency (Reference ) Types of Germline Mutations Observed Mutation Location
CS PTEN 9 13–81% (4, 9–12 ) o point nonsense o exons 2– 9
o point missense o clusters in exons 5,* 7,y and 8.z
o microdeletions
o microinsertions
o microdeletion – insertions
o splice site
BRR PTEN 9 50–60% (5, 8 ) o ‘‘as above’’ o ‘‘as above’’
o gross hemizygous deletion
o balanced translocation
MEN 2 RET 20 >92% (6, 13 ) o point missense o exon 10 ( codons 609, 611, 618, 620 )
o exon 11 ( codons 630, 634 )
o exon 13 ( codons 768, 790, 791 )
o exon 14 ( codon 804 )
o exon 15 ( codon 883 [MEN 2B only ], 891 )
o exon 16 ( codon 918 [ 95% of MEN 2B ] )
VHL VHL 3 75–100% (14–16 ) o point nonsense o all exons
o point missense
o microdeletions
o microinsertions
o microdeletion – insertions
o splice site
o gross hemizygous deletion
o complex rearrangements
*Exon 5 encodes the protein tyrosine phosphatase core motif of PTEN.
y,zExons 7 and 8 are believed to encode the potential tyrosine and serine phosphorylation sites ( reviewed in Ref. [ 17 ] ).
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Denaturing HPLC
DHPLC was undertaken on a WAVE DNA fragment
analysis system (Transgenomic, Omaha, NE). Two to five
microliters of heteroduplexed PCR fragments was injected
onto the DNASep cartridge. Products were eluted at a
constant flow rate of 0.9 ml /min with a linear acetonitrile
gradient determined by WAVEMaker software (Transge-
nomic, Omaha, NE) based on the size and GC content of the
amplicon. The gradient was achieved by combining 0.1 M
triethylammonium acetate (TEAA) buffer (pH 7) (Trans-
genomic) and Buffer B (0.1 M TEAA with 25% acetonitrile )
(Transgenomic). Eluted DNA fragments were detected by
the system’s UV detector and analyzed as chromatograms.
The processing time for each sample was comprised of a
2.2-minute lag for the detector, 0.5 minutes loading with a
5% decrease in Buffer B, a 4.5-minute linear gradient with a
slope of 2% increase in Buffer B per minute, a 0.5-minute
cleaning stage using 75% acetonitrile, and a 0.9-minute
equilibration before the next injection. Homo- and hetero-
duplex peaks were detected between the initial injection
peak, produced by residual nucleotides and primers in the
reaction, and the wash peak, produced by the acetonitrile
flush at the end of each analysis.
Melt profiles were constructed using the WAVEMaker
software (Transgenomic) using PCR fragments in the size
range of 178 to 344 base pairs (non–GC-clamped frag-
ments) and 218 to 396 base pairs (GC-clamped fragments).
A range of partial denaturation temperatures was predicted
by this software (Table 3). PCR products were initially
analyzed under nondenaturing conditions, 508C, to assess
the quality of the peak representing both hetero- and
homoduplex DNA fragments in a mutant sample. All
temperatures within the predicted range for partial denatura-
tion were then assessed for their ability to resolve homo- and
heteroduplexes. A single temperature was chosen where all
mutants could be resolved. Given that heteroduplexes are
Table 3. Mutation Summary and Temperatures for Detection Using the WAVE.
Gene Family
Identifier
Exon Mutation /Polymorphism Predicted
temperature range
(GC -clamped fragment )
Predicted
temperature range
(non GC-clamped fragment )
Temperature of
mutant detection
PTEN Ban1 2 A34D 56–578C 54–568C 578C*
CDdl R47G
Ban2 3 Y68H 55–578C 54–568C 568C*
CDmy IVS2 -2A>G
CDcl 5Iy Q110X 59–618C 58–608C 608C*; 598C
Cdve c.302–304delTCAinsCC
Ban4 C105Y
Ban5 c.347delG
CDst c.347–351delACAAT
CDtm 5IIy R130X 58–608C 57–598C 598C*; 588C
Ban7 I135V
Ban9 6 c.520–544del25 58–608C 58–608C 598C*
Ban10 IVS6+5G>T
Ban8 S170R
Ban11 7 R233X 58–608C 57–598C 598C*; 588C
B /CS5 IVS6 -1G>C
B /CS7 8 c.987–990TAAAdel 56–588C 56–588C 578C*; 578C
Ban15 c.950–953delTACT
CD93 R335X
B /CS6 IVS7 -4insT
Ban14 c.886insCT
RET 073 10 C618R N/A 66–688C 668C
023 C620R
029 11 C634R N/A 65–678C 658C
126 C634G
068 C634Y
144 C634S
041 15 A883Fz;S904S N /A 63–658C 638C
180 -01 S891A
180 -02 S891A;S904S
181 S904S
174 16 M918T N /A 59–608C 598C
VHL V01 3 T157I N /A 60–628C 618C
V02 R161X
*Temperatures indicated for GC-clamped fragments only.
yPTEN exon 5 is amplified in two amplicons.
z508C will detect A883F (Figure 2C ) but not S904S.
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less stable, they denatured earlier than the homoduplexes
and so were seen first in the elution profile.
Results
Thirty - two known mutations and one polymorphism previ-
ously determined by sequence analysis and/or restriction
endonuclease digestion, 21 in PTEN, 9 in RET plus a
polymorphism, and 2 in VHL, were detected by dHPLC at
temperatures within the range predicted by the WAVEMaker
software (Transgenomic) (Table 3). The mutation R47G in
exon 2 of PTEN identified in a family with CS has not been
previously reported. The clinical symptoms of CS in this
family included gastrointestinal polyps, multiple fibroadeno-
mas of the breast, Hashimoto’s thyroiditis and goiter,
lipomas, and papules of the oral mucosa.
The value of GC-clamped primers for use in dHPLC
mutation detection was directly assessed in four PTEN
exons or amplicons — 5I, 5II, 7, and 8. Two to five separate
mutations, well scattered over the exon, were analyzed in
each case for detection of all mutants at a single temper-
ature. The nonsense PTEN point mutation R233X in exon 7
was poorly discernible when analysis was undertaken using
non–GC-clamped primers at all temperatures predicted by
the WAVEMaker software (Transgenomic). In addition,
temperatures up to 708C, at which the peak had largely
collapsed, were unable to resolve this mutant. However,
resolution of the heteroduplexed fragments was clearly
observed using a PCR amplicon generated by identical
primers with the addition of a GC-clamp (Figure 1A ). Of
interest, the elution profile of the wild- type DNA of GC-
clamped PTEN exon 7 shows an apparent peak preceding
the homoduplex peak (Figure 1A ). This peak was not
observed in non–GC-clamped PTEN exon 7. The same
wild- type DNA was used for both experiments and shown by
sequence analysis to be free of sequence variants. It is most
likely that this apparent peak represents an artifact intro-
duced by the GC clamp. Clearly, however, the GC-clamped
PTEN exon 7 wild type shows a distinctly different elution
profile to both the R233X and IVS6-1G>C exon 7 mutants.
Artifact peaks before the appearance of homo- and
heteroduplex peaks in the elution profile likely due to the
method of sample preparation were also detected (Figure
2A ). These artifact peaks could be decreased relative to true
homo- and heteroduplex peaks by dilution of the template
DNA before PCR amplification, excluding the possibility that
they represented true peaks. The presence of artifacts
highlights the importance of including wild- type DNA
controls in each experiment.
An intronic polymorphism present in amplicon 8, IVS8+32
T/G [28] was not detectable at the temperature used for
mutation analysis of exon 8 (Table 3, data not shown). This
Figure 1. dHPLC analysis of PTEN exons or amplicons. (A ) PTEN exon 7 analyzed as both a GC-clamped and a non–GC-clamped fragment. The mutation
R233X is scarcely detectable in the elution profile of the nonclamped exon 7 fragment compared to the GC-clamped fragment. Increased resolution of the elution
profile is also observed for the splice site mutation IVS6 -1G>C. (B ) PTEN amplicon 5I analyzed as both a GC-clamped and a non–GC-clamped fragment. Two
missense point mutations, C105Y and Q110X, a small deletion– insertion, c.302–304delTCAinsCC, and a deletion, c347–351delACAAT, were able to be
discriminated from the wild - type sequence using non–GC-clamped primers, however, resolution was significantly improved using primers with a GC clamp.
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was likely due to this variant’s location in an almost fully
denatured region of the melt profile. In general, the use of
GC-clamped primers for PCR amplification of PTEN greatly
improved the resolution of hetero- and homoduplex peaks,
dramatically improving the efficiency of user interpretation
(Figure 1, A and B ).
Given the clustered nature of RET mutations, dHPLC
was optimized using non–GC-clamped primers (Table 3).
All nine missense mutations were able to be differentiated
from the wild- type DNA homoduplexes in the four exons
analyzed (Figure 2, A–E ). C634G and C634S in RET
exon 11 (Figure 2B ) showed more subtle changes in their
elution profiles, yet were still discernible from wild- type
DNA. A silent polymorphism in RET exon 15 resulting from
a C!G substitution, S904S, was detected at 638C (Figure
2D ) [29]. This polymorphism was also present in the
individual shown to carry the A883F mutation (041, Table
3). Of interest, this polymorphism was not detected at
Figure 2. dHPLC analysis of RET and VHL exons. (A–E ) Nine clustered mutations and a polymorphism in RET exon 10, 11, 15, and 16 were able to be resolved.
C618R and C620R (exon 10 ), C634R and C634Y (exon 11 ), A883F, S891A and S904S (exon 15 ), and M918T (exon 16 ) showed elution profiles distinctly
resolvable from the wild - type amplicon for each exon. C634G and C634S (exon 11 ) showed elution profiles with more subtle variation from wild - type exon 11. (F )
The elution profiles of two missense point mutations in VHL exon 3, T157I and R161X, were clearly distinct from wild - type sequence.
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508C in the wild- type DNA, subsequently shown by
sequence analysis to be positive for S904S. However,
DNA from individual 041 containing both the A883F
mutation and the S904S polymorphism did form hetero-
duplexes at this temperature (Figure 2C ). The mutant
S891A was unable to be resolved at 508C. Therefore, even
though the polymorphism was unable to be detected at
508C, thus excluding it as a normal variant in the elution
profile, the inability to detect all RET exon 15 mutants at
this temperature excluded the possibility of conducting
mutation scanning at this temperature.
Only two VHLmutants, mapping within nine nucleotides of
each other in VHL exon 3, were available for analysis. Again,
given the close proximity of these mutants, dHPLC was
optimized using non–GC-clamped primers (Table 3, Figure
2F ). Further, dHPLC was used to screen four additional
asymptomatic at - risk members of one of the VHL families,
V02. The elution profile for all asymptomatic individuals,
aged 5 to 11 years, matched that of the proband and was
clearly different to wild- type DNA analyzed as a control in the
same experiment. Sequence analysis confirmed that these
individuals were positive for R161X.
Discussion
The underlying primary genetic mutations associated with
an increasing number of familial cancer syndromes are
rapidly being identified. Greater understanding of the
molecular basis of many of these inherited syndromes
allows for the development of efficient genetic screening
programs to identify family members at risk of developing
cancer, thus allowing directed cancer surveillance for
mutation carriers. We have employed a dHPLC system,
WAVE DNA fragment analysis system (Transgenomic), for
rapid germline mutation screening in two tumor suppressor
genes, PTEN and VHL, and one oncogene, RET, mutations
of which are associated with CS, VHL disease, and MEN 2,
respectively. The efficiency of mutation detection in PTEN
was increased by the use of GC-clamped primers resulting
in 100% (N=32) of mutations plus a polymorphism being
identified by dHPLC. These mutations had previously been
identified by the more labor- intensive techniques of DGGE
and TTGE (PTEN ) [4,5 ]; sequencing and/or restriction
endonuclease digestion (PTEN, VHL, and RET )
[4,5,16,30]. In addition, dHPLC was used to provide a rapid
screen of four asymptomatic individuals, age range 5 to 11
years, of unknown genetic carrier status in the VHL family
V02. All individuals were shown to be positive for the R161X
mutation and appropriate, directed cancer surveillance has
now been recommended for these patients.
Although mutation hot spots are seen in many of the
tumor suppressor genes linked to familial cancer syndromes,
in general, germline mutations are scattered largely along
the entirety of the gene [31–33]. Germline mutation of PTEN
in CS and BRR also follows this pattern, making efficient
dHPLC mutation detection at a single temperature for each
specific amplicon impossible due to variation of the
fragment’s melt profile. For reliable mutation detection using
non–GC-clamped primers, analyses will need to be
performed at multiple temperatures to ensure detection of
all mutants as has been previously reported [34]. In general,
the use of GC-clamped primers allows the generation of a
more uniform melt profile, thus leading to improved
resolution of hetero- and homoduplex peaks in the elution
profile. Analyses performed at a single temperature are then
more likely to generate elution profiles clearly defining
mutant samples, regardless of the position of the mutation
in the amplicon. In a direct comparison of GC-clamped and
non–GC-clamped PTEN amplicons, mutants that were
poorly discernible as nonclamped fragments were able to
be clearly resolved when generated as part of a GC-
clamped amplicon (Figure 1 ). Perhaps the most dramatic
example of this increased resolution was seen in the case of
the germline mutant R233X (Figure 1A ). This mutant was
reported in a study of somatic PTEN mutations in small cell
lung carcinoma using dHPLC where it was also shown to be
poorly resolved [35]. In general, the use of GC-clamped
primers for dHPLC greatly improved the resolution of homo-
and heteroduplex peaks, clearly improving the efficiency of
this methodology.
Similar to other more traditional mutation scanning
methods such as DGGE and SSCP, the presence of
polymorphisms can present a complicating factor when
using dHPLC to screen for germline mutations. Although a
known intronic polymorphism in PTEN, IVS8+32 T/G, was
not detected at the temperature chosen to screen for
mutants, the RET polymorphism S904S was clearly evident
in the elution profile of the fragment containing RET exon 15
(Figure 2D ). The inability to detect the PTEN intronic
polymorphism was likely due to its location in an almost fully
denatured region of the melt profile. However, the presence
of the RET exon 15 polymorphism likely influenced the
elution profile of the A883F mutant, as the single patient with
this mutation, a case of de novo MEN 2B, also had this
polymorphism (Figure 2D ). An earlier study using dHPLC to
screen for RET mutations only analyzed exon 10 mutants
[34]. To date, polymorphisms have not been reported in this
exon. The presence of polymorphisms must be considered
when using dHPLC to screen members of hereditary cancer
families at risk of inheriting the disease allele.
A second genetic aberration that complicates screening
with dHPLC is gross germline deletion. To date, gross
germline deletion of PTEN has not been reported to be
associated with CS; however, three cases of gross germ-
line deletion of the 10q23 region encompassing PTEN have
been reported [5,36,37]. Gross germline deletion of VHL
and its flanking intervals is a more common phenomenon
and has been reported in up to 25% of VHL families [7]. It
is important to recognize that dHPLC would be an
unsuitable mutation detection method in cases of germline
whole gene deletion as the presence of only one wild- type
allele would preclude the formation of heteroduplexes and
thus a definitive elution profile. In the case of VHL
screening, dHPLC could be used as an initial screen for
the detection of germline intragenic mutations. If no
mutations were detected in this first screen, DNA from
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probands of these families could undergo alternative
screening to detect putative deletions of the entire VHL
gene using methods such as quantitative Southern blotting
or fluorescence in situ hybridization as have been pre-
viously recommended [16].
The arising complication from the presence of a single
allele when screening with dHPLC is also relevant when
studying somatic mutations of tumor suppressor genes in
tissues where the wild- type allele is lost. A study of somatic
PTEN mutation by dHPLC in 63 malignant gliomas showed
that low- level amounts of normal contaminant DNA, 10% to
20%, enabled the formation of detectable heteroduplexes in
13 samples where the wild- type PTEN allele had been lost
and a mutation was present in the retained allele [34].
However, perhaps more reliably for the analysis of DNA
from tumor tissue, wild - type PCR product could be admixed
with the tumor or cell line PCR product known to show allelic
loss to mimic the presence of a wild - type allele, then
denatured, reannealed and screened for heteroduplex
peaks by dHPLC [35].
Given the examples of VHL and PTEN where whole gene
deletion has been identified in the germline, a wild- type
allele is also retained. Therefore the method of admixing
wild- type DNA with a test sample would not be suitable for
germline DNA analyses.
A number of studies have been performed to directly
compare dHPLC with the more established mutation
detection methodologies of single-strand conformation
polymorphism and heteroduplex analysis. In studies of
known mutations of BRCA1, the cystic fibrosis transmem-
brane conductance regulator gene, CFTR, and the tuberous
sclerosis complex genes, TSC1 and TSC2, dHPLC detected
96% to 100% of mutations, SSCP 85% to 94%, and
heteroduplex analysis only 82% [31,38]. In a further study
of 150 unrelated cases with tuberous sclerosis, dHPLC was
shown to detect mutations in 68% of cases, SSCP in 61%
and heteroduplex analysis in only 58% [39]. In addition, a
blinded comparison of DGGE and dHPLC used to screen
BRCA1 in 41 probands from hereditary breast and ovarian
cancer families showed that dHPLC was able to detect
a mutant that was not identified by DGGE [40]. To
date, no false-positives have been identified using dHPLC
[31,33,34,41].
In summary, we have described a novel application for
GC-clamped amplicons to increase the sensitivity of
dHPLC allowing accurate screening at a single temperature
of the tumor suppressor gene PTEN associated with CS
and the related syndrome BRR. This method has applic-
ability to other tumor suppressor genes associated with
familial cancer syndromes including BRCA1, BRCA2, and
MEN1 where mutations are scattered largely along the
entirety of the gene. When planning the implementation of a
germline genetic screening program for inherited cancer
syndromes incorporating dHPLC, it is essential to take into
consideration the spectrum of mutations, including gross
germline deletion and polymorphisms, that have been
previously described to permit accurate interpretation of
dHPLC elution profiles.
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